Q4 2025 13F Holders as of 31 Dec 2025
-
Type / Class
-
Equity / Ordinary Shares, no par value
-
Shares outstanding
-
182,917,028
-
Total 13F shares
-
182,725,550
-
Share change
-
+19,883,825
-
Total reported value
-
$3,107,724,831
-
Put/Call ratio
-
86%
-
Price per share
-
$17.00
-
Number of holders
-
214
-
Value change
-
+$421,310,913
-
Number of buys
-
138
-
Number of sells
-
86
Institutional Holders of Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) as of Q4 2025
As of 31 Dec 2025,
Wave Life Sciences Ltd. - Ordinary Shares, no par value (WVE) was held by
214 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
182,725,550 shares.
The largest 10 holders included
GSK plc, RA CAPITAL MANAGEMENT, L.P., FMR LLC, BlackRock, Inc., ADAGE CAPITAL PARTNERS GP, L.L.C., MAVERICK CAPITAL LTD, PRICE T ROWE ASSOCIATES INC /MD/, Darwin Global Management, Ltd., Driehaus Capital Management LLC, and M28 Capital Management LP.
This page lists
214
institutional shareholders reporting positions in this security
for the Q4 2025 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.